AUGMENT-101 Trial

FDA Expands Revumenib Approval to NPM1-Mutant Relapsed/Refractory AML in Patients 1 and Older

The decision follows a priority review supported by AUGMENT-101 results demonstrating meaningful remission in a heavily pretreated NPM1-mutant population.